Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

TG Therapeutics Q3 EPS $2.43 Beats $0.22 Estimate, Sales $161.709M Beat $152.169M Estimate

Author: Benzinga Newsdesk | November 03, 2025 07:02am
TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $2.43 per share which beat the analyst consensus estimate of $0.22 by 999.55 percent. This is a 12050 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $161.709 million which beat the analyst consensus estimate of $152.169 million by 6.27 percent. This is a 92.79 percent increase over sales of $83.879 million the same period last year.

Posted In: TGTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist